{"organizations": [], "uuid": "971a408ba1a1b48a92b3480b9cf13d759b32a3b4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-titan-in-discussions-with-braeburn/brief-titan-in-discussions-with-braeburn-regarding-u-s-probuphine-commercialization-idUSFWN1PH0FY", "country": "US", "domain_rank": 408, "title": "BRIEF-Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T14:04:00.000+02:00", "replies_count": 0, "uuid": "971a408ba1a1b48a92b3480b9cf13d759b32a3b4"}, "author": "", "url": "https://www.reuters.com/article/brief-titan-in-discussions-with-braeburn/brief-titan-in-discussions-with-braeburn-regarding-u-s-probuphine-commercialization-idUSFWN1PH0FY", "ord_in_thread": 0, "title": "BRIEF-Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "canaccord genuity", "sentiment": "none"}, {"name": "commercialization reuters staff  titan pharmaceuticals inc", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 22, 2018 / 12:05 PM / in 6 minutes BRIEF-Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization Reuters Staff \nTitan Pharmaceuticals Inc: \n* TITAN IN DISCUSSIONS WITH BRAEBURN REGARDING U.S. PROBUPHINE® COMMERCIALIZATION \n* TITAN PHARMACEUTICALS - ‍HAS BEEN IN PRELIMINARY DISCUSSIONS WITH BRAEBURN FOR RETURN OF U.S. COMMERCIALIZATION RIGHTS TO PROBUPHINE​ \n* TITAN PHARMACEUTICALS - ‍HAS RETAINED CANACCORD GENUITY TO ASSIST IN EFFORT AS PART OF EVALUATION OF STRATEGIC AND FINANCIAL ALTERNATIVES​ \n* TITAN PHARMACEUTICALS - ‍BELIEVES IT IS APPROPRIATE TO SEEK A NEW PARTNER THAT CAN BETTER FOCUS ON SUCCESSFUL COMMERCIALIZATION STRATEGY FOR PROBUPHINE​ \n* TITAN PHARMACEUTICALS - BRAEBURN‘S RECEIPT OF CRL FROM U.S. FDA FOR BUPRENORPHINE PRODUCT NDA LIKELY TO NEGATIVELY IMPACT ITS PROBUPHINE MARKETING Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T14:04:00.000+02:00", "crawled": "2018-01-22T15:01:32.011+02:00", "highlightTitle": ""}